$PROF

Profound Medical expects Q3 revenue could top estimates by 47% (PROF:NASDAQ)

Profound Medical (PROF) anticipates Q3 revenue of $9.8M-$10.0M, a 85%-89% YoY and 292%-300% QoQ increase, surpassing estimates by 45%-47%. Gross margin is expected to exceed 70%.

Original reporting
Published Oct 7, 2026, 8:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 8:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PROF
Bullish
high confidence
Mentioned
$PROF
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$PROFBullishMed
01

Why it matters

The guidance lift is the first report of the company's Q3 outlook, providing new data for traders.

02

Market read

First‑report guidance beat for a micro‑cap; may trigger short‑term price move.

03

What to watch

Potential supply‑chain constraints or regulatory hurdles could temper revenue growth.

Relevance 6/10Novelty 7/10Timing: pre‑market today

Background

Profound Medical (NASDAQ:PROF) is a micro‑cap developer of AI‑guided robotic surgery platforms.

Company-level read

Ticker impact

$PROFBullishHigh confidence
Context

Profound Medical raised its Q3 revenue guidance to $9.8M-$10.0M, about 45%-47% above consensus.

Expected impact

likely upward pressure as the market absorbs the strong guidance lift

Evidence & confidence

The guidance is a fresh, material disclosure that exceeds consensus by a large margin, prompting potential buying.

Market effects

May boost sentiment for the broader medical device/AI‑assisted surgery sector.

Limited to U.S. small‑cap investors; negligible regional effect.

Low global relevance given the company's micro‑cap size.

Counterpoint

The guidance could be overly optimistic; execution risk may lead to a pull‑back if sales lag.

Key entities

  • Profound Medical

    AI‑enabled surgical robotics firm.

Related articles

$PROFMed

Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg…

Profound Medical Corp. (PROF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue Anticipates Q3-2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg analyst consensus by approximately 45% to 47% TORONTO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (N

$PROFMed

Profound Medical Reports Second Quarter 2026 Financial Results

Profound Medical Corp. (PROF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Profound Medical Reports Second Quarter 2026 Financial Results – Operating expenses decline 16%, helping drive a 39% improvement in net loss – – Approximately $3.1 million of TULSA revenue recognition shifts into early Q3 due to shipment timing – – Strong clinical, c

$005930.KSHighAI 9/10

Samsung Q3 profit surges to record high, but misses lofty expectations

Samsung Electronics (KS:005930) reported a record Q3 operating profit of 107.40 trillion won, up nearly tenfold YoY, but slightly below Bloomberg's 108.67 trillion won estimate. Sales more than doubled to 195 trillion won. The surge was driven by AI-fueled demand for memory chips, though smartphone and consumer electronics divisions faced pressure. A stronger South Korean won may have impacted earnings.

$005930.KSMedAI 9/10

Samsung Electronics’ quarterly operating profit tops 100 trillion won for the first time... companywide operating margin nears 55%

Samsung Electronics reported record quarterly operating profit of 107.4 trillion won, with revenue of 195 trillion won, exceeding market expectations. The company's operating margin reached 54.8%, the highest among tech companies. Revenue and profit increased significantly year-on-year and quarter-on-quarter. Analysts expect continued strong performance in the fourth quarter.